Fusion Antibodies (FAB) Competitors GBX 6.89 +0.34 (+5.21%) (As of 12/20/2024 11:56 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider Trades FAB vs. OKYO, OPTI, OBI, AOR, RLM, NSCI, ONC, SNG, BVX, and APTAShould you be buying Fusion Antibodies stock or one of its competitors? The main competitors of Fusion Antibodies include OKYO Pharma (OKYO), OptiBiotix Health (OPTI), Ondine Biomedical (OBI), AorTech International (AOR), Realm Therapeutics (RLM), NetScientific (NSCI), Oncimmune (ONC), Synairgen (SNG), BiVictriX Therapeutics (BVX), and Aptamer Group (APTA). These companies are all part of the "biotechnology" industry. Fusion Antibodies vs. OKYO Pharma OptiBiotix Health Ondine Biomedical AorTech International Realm Therapeutics NetScientific Oncimmune Synairgen BiVictriX Therapeutics Aptamer Group Fusion Antibodies (LON:FAB) and OKYO Pharma (LON:OKYO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, community ranking, profitability, institutional ownership, analyst recommendations, earnings and valuation. Does the media refer more to FAB or OKYO? In the previous week, OKYO Pharma had 1 more articles in the media than Fusion Antibodies. MarketBeat recorded 1 mentions for OKYO Pharma and 0 mentions for Fusion Antibodies. Fusion Antibodies' average media sentiment score of 0.00 equaled OKYO Pharma'saverage media sentiment score. Company Overall Sentiment Fusion Antibodies Neutral OKYO Pharma Neutral Is FAB or OKYO more profitable? OKYO Pharma has a net margin of 0.00% compared to Fusion Antibodies' net margin of -195.95%. Fusion Antibodies' return on equity of -152.68% beat OKYO Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Fusion Antibodies-195.95% -152.68% -63.78% OKYO Pharma N/A -397.13%-154.72% Do institutionals and insiders believe in FAB or OKYO? 21.0% of Fusion Antibodies shares are owned by institutional investors. 11.4% of Fusion Antibodies shares are owned by insiders. Comparatively, 31.9% of OKYO Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk and volatility, FAB or OKYO? Fusion Antibodies has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500. Which has stronger earnings & valuation, FAB or OKYO? Fusion Antibodies has higher revenue and earnings than OKYO Pharma. Fusion Antibodies is trading at a lower price-to-earnings ratio than OKYO Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFusion Antibodies£1.14M5.76-£2.19M-£0.04-172.28OKYO PharmaN/AN/A-£6.70M-£0.01N/A Does the MarketBeat Community believe in FAB or OKYO? Fusion Antibodies received 47 more outperform votes than OKYO Pharma when rated by MarketBeat users. Likewise, 68.35% of users gave Fusion Antibodies an outperform vote while only 63.64% of users gave OKYO Pharma an outperform vote. CompanyUnderperformOutperformFusion AntibodiesOutperform Votes5468.35% Underperform Votes2531.65% OKYO PharmaOutperform Votes763.64% Underperform Votes436.36% SummaryFusion Antibodies beats OKYO Pharma on 8 of the 13 factors compared between the two stocks. Ad Porter & CompanyHow to piss off your liberal friends… and profit from itElon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get Fusion Antibodies News Delivered to You Automatically Sign up to receive the latest news and ratings for FAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FAB vs. The Competition Export to ExcelMetricFusion AntibodiesBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£6.57M£165.68M£5.14B£1.91BDividend YieldN/A3.64%5.09%5.45%P/E Ratio-172.28115.5190.051,871.08Price / Sales5.7618,531.021,116.25393,610.87Price / Cash9.0212.8743.1028.67Price / Book3.458.594.782.81Net Income-£2.19M-£20.67M£120.31M£155.88M7 Day Performance6.84%-1.05%-1.92%-2.02%1 Month Performance56.76%174.77%13.65%21.69%1 Year Performance62.14%134.18%28.34%29.83% Fusion Antibodies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FABFusion AntibodiesN/AGBX 6.89+5.2%N/A+53.1%£6.57M£1.14M-172.2848Gap UpOKYOOKYO PharmaN/AGBX 1.40-24.3%N/AN/A£23.24MN/A-140.007News CoverageGap DownOPTIOptiBiotix HealthN/AGBX 22.60+6.6%N/A-26.9%£22.13M£1.26M-753.331High Trading VolumeOBIOndine BiomedicalN/AGBX 7.75+2.0%N/A-6.2%£21.49M£1.63M-258.33N/AAORAorTech InternationalN/AN/AN/AN/A£19.99M£539,000.00-33.383RLMRealm TherapeuticsN/AGBX 11.50flatN/AN/A£13.41M£501,919.00-0.66N/ANSCINetScientificN/AGBX 53.50flatN/AN/A£12.81M£1.45M-486.3626ONCOncimmuneN/AGBX 15.85+8.1%N/A-41.3%£11.75M£1.21M-528.3352SNGSynairgenN/AGBX 4.38-0.2%N/A-70.1%£8.82M£79,000.00-144.7334Gap DownBVXBiVictriX TherapeuticsN/AGBX 10+17.6%N/AN/A£8.25MN/A-250.0017Gap UpHigh Trading VolumeAPTAAptamer GroupN/AN/AN/A-69.6%£8.06M£1.03M-4.7837Positive NewsHigh Trading Volume Related Companies and Tools Related Companies OKYO Pharma Alternatives OptiBiotix Health Alternatives Ondine Biomedical Alternatives AorTech International Alternatives Realm Therapeutics Alternatives NetScientific Alternatives Oncimmune Alternatives Synairgen Alternatives BiVictriX Therapeutics Alternatives Aptamer Group Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:FAB) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThis is the worst sign for the U.S. stock market in 50 yearsThe Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts no...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fusion Antibodies plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Fusion Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FAB Stock Alerts